Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Centro Médico Imbanaco (CMI) in Cali, further expanding the company’s presence in Colombia’s attractive private hospital market.

CMI is located in a central district of Cali, the biggest city in southwestern Colombia with a population of 2.4 million. As one of the most prestigious private hospitals in Latin America, repeatedly recognized for its medical quality as well as its state-of-the-art infrastructure and medical technology, CMI offers a comprehensive range of medical specialties and services. The hospital has about 350 beds, 17 operating rooms and 250 consultation rooms, and generated sales of about €130 million in 2018. The total consideration amounts to approximately €300 million.

The purchase of CMI is another important step in strengthening Quirónsalud’s presence in Colombia’s growing and consolidating healthcare services market. With this acquisition, Quirónsalud becomes one of the leading private hospital operators in the country. The transaction is expected to close in the first quarter of 2020, pending anti-trust clearance. Fresenius expects CMI to be accretive to Group net income¹ in fiscal year 2020.

¹Net income attributable to shareholders of Fresenius SE & Co. KGaA

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Centro Médico Imbanaco (CMI) in Cali, further expanding the company’s presence in Colombia’s attractive private hospital market.

CMI is located in a central district of Cali, the biggest city in southwestern Colombia with a population of 2.4 million. As one of the most prestigious private hospitals in Latin America, repeatedly recognized for its medical quality as well as its state-of-the-art infrastructure and medical technology, CMI offers a comprehensive range of medical specialties and services. The hospital has about 350 beds, 17 operating rooms and 250 consultation rooms, and generated sales of about €130 million in 2018. The total consideration amounts to approximately €300 million.

The purchase of CMI is another important step in strengthening Quirónsalud’s presence in Colombia’s growing and consolidating healthcare services market. With this acquisition, Quirónsalud becomes one of the leading private hospital operators in the country. The transaction is expected to close in the first quarter of 2020, pending anti-trust clearance. Fresenius expects CMI to be accretive to Group net income* in fiscal year 2020.

*Net income attributable to shareholders of Fresenius SE & Co. KGaA

Busulfan, a drug for certain blood cancers, expands the company’s broad oncology portfolio.

Dicyclomine Hydrochloride Injection, an antispasmodic agent, expands Fresenius Kabi’s large and growing generic critical care portfolio.  

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 95 KB)

Dr. Karl Schneider, a longtime member of the Supervisory Board of Fresenius, has decided to retire from the Supervisory Board of Fresenius Management SE on December 31, 2019. He joined this body in May 2010. From April 1991 until January 2011, Dr. Schneider was a member of the Supervisory Board of Fresenius AG (Fresenius SE starting in July 2007, now Fresenius SE & Co. KGaA), serving as Chairman between 1998 and 2003.

The Supervisory Board and annual general meeting of Fresenius Management SE have named Dr. Schneider as an honorary member of the Supervisory Board of Fresenius Management SE. This appointment recognizes his invaluable, decades-long work on behalf of Fresenius.

An engineer and holder of a doctoral degree in agricultural science, Dr. Schneider was a member of the Management Board of Südzucker AG from 1982 to 1993, and Chief Executive Officer from 1988. He is Deputy Chairman of the Foundation Council of the Else Kröner-Fresenius Foundation. Established in 1988 by Fresenius’ former owner, the late Else Kröner, the foundation is the company’s largest shareholder.

Dr. Gerd Krick, Chairman of the Supervisory Board of Fresenius Management SE and Fresenius SE & Co. KGaA, commented on the departure of his longtime colleague: “Karl Schneider’s work for Fresenius deserves the highest possible recognition and appreciation. He has been closely involved with our company for decades, always giving his full commitment and support to the successful development of Fresenius. On behalf of the Supervisory Board, the Management Board and all the employees, I want to express our great thanks to him. I sincerely wish him all the best, and good health, in the coming years.”

Joining the Supervisory Board of Fresenius Management SE will be Wolfgang Kirsch, who has been elected as a member starting on January 1, 2020. Kirsch joined the Management Board of DZ BANK AG in Frankfurt in 2002 and served as CEO from September 2006 until December 2018. In 2016, under his direction, DZ BANK and WGZ BANK merged into today’s DZ BANK.

“In Wolfgang Kirsch we are welcoming an expert with tremendous experience, especially in financial areas, to our Supervisory Board,” said Dr. Krick. “We are looking forward to working with him.”